The human microbiome is no longer viewed as a passive collection of commensals but as a dynamic endocrine organ capable of modulating systemic immunity. Among the diverse taxa inhabiting the gastrointestinal tract, Enterococcus gallinarum has emerged as a high-priority organism of interest. While traditionally known as a motile, vancomycin-resistant commensal, cutting-edge research has identified its pivotal—and sometimes controversial—role in autoimmune pathogenesis and mucosal barrier integrity.
Welcome to our specialized service portal dedicated to Enterococcus gallinarum, a unique pathobiont that has emerged as a focal point in next-generation microbiome research. As a leading Contract Research Organization (CRO) specializing in Live Biotherapeutic Products (LBPs), Creative Biolabs provides the end-to-end preclinical infrastructure necessary to translate the complex biology of E. gallinarum into breakthrough therapies for autoimmune disorders, oncology, and metabolic health.
Overview: The Dual Nature of E. gallinarum
Enterococcus gallinarum is a Gram-positive, facultative anaerobic bacterium traditionally known for its intrinsic, low-level resistance to vancomycin (mediated by the vanC gene). While once considered a simple commensal of the intestinal tract, recent landmark studies have identified it as a "pathobiont"—a resident microbe that can trigger disease under specific genetic or environmental conditions.
The therapeutic interest in E. gallinarum is twofold:
-
Targeted Inhibition: Researchers are developing vaccines, phages, and small molecules to eliminate it, as its translocation from the gut to the liver and systemic circulation is a known trigger for Systemic Lupus Erythematosus (SLE) and Autoimmune Hepatitis.
-
Immune Modulation: Due to its potent ability to induce TH17 cell differentiation, it is being explored as a "biological adjuvant" to enhance the efficacy of cancer immunotherapies, particularly in "cold" tumors that lack sufficient immune infiltration.
Our Preclinical Research Services
As a CRO, we offer a comprehensive suite of services tailored specifically to Enterococcus gallinarum research, ensuring your drug candidate meets the rigorous standards required for IND (Investigational New Drug) filing.
We provide specialized animal models to study the unique behavior of this strain:
-
Translocation Models: Using genetically susceptible mice to track the movement of E. gallinarum from the gut to internal organs.
-
Germ-Free & Gnotobiotic Services: Colonizing sterile mice with specific E. gallinarum strains to isolate its effects from other microbiota.
-
Oncology Synergy Models: Testing LBP candidates in combination with chemotherapy or immunotherapy in tumor-bearing mice.
Product Offerings for Preclinical Research
To accelerate your laboratory workflows, we provide high-quality biological materials:
|
Product Name
|
Catalog No.
|
Target
|
Product Overview
|
Datasheet
|
Price
|
|
Enterococcus gallinarum Genomic DNA
|
LBGF-0925-GF86
|
Enterococcus DNA
|
This product contains high-quality, intact genomic DNA isolated from Enterococcus gallinarum. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
|
Datasheet
|
$720.00
|
Research Applications: Targeting Disease with Precision
The clinical relevance of E. gallinarum spans multiple therapeutic areas. Our research services are designed to help you explore its role in the following:
Recent evidence indicates that E. gallinarum can spontaneously breach the intestinal barrier. Once it reaches the liver and mesenteric lymph nodes, it induces the production of auto-antibodies and pro-inflammatory cytokines. Evaluating how "leaky gut" conditions facilitate translocation and testing therapeutic interventions (e.g., specific antibiotics or vaccines) to suppress its systemic effects.
2. Cancer Immunotherapy
While detrimental in autoimmunity, the pro-inflammatory nature of E. gallinarum is a potential asset in oncology. By stimulating TH17 responses, this strain may improve the performance of Immune Checkpoint Inhibitors (ICIs). Investigating the synergy between E. gallinarum colonization and anti-PD-1/PD-L1 therapies.
3. Chronic Inflammatory Conditions
Beyond the liver, E. gallinarum has been implicated in driving systemic inflammation via the TLR8 pathway, making it a target for research into broader inflammatory syndromes.
Why Choose Us? Our Advantages
Deep Domain Expertise
We don't just provide lab space; our PhD-level scientists are experts in the specific "pathobiont" biology of E. gallinarum.
Gnotobiotic Excellence
Our state-of-the-art germ-free facilities allow for the most precise microbiome-host interaction studies available.
Regulatory-Ready Data
All our preclinical studies are performed with a focus on future regulatory submissions, providing you with robust, reproducible data.
Customizable Platforms
From single-strain evaluations to complex microbial consortia, we adapt our models to your specific therapeutic hypothesis.
The era of "one-size-fits-all" probiotics is over. The future lies in precision microbiome modulation. Understanding the subtle nuances of Enterococcus gallinarum—from its motility to its interaction with the liver—is key to unlocking new treatments for systemic autoimmune disorders that currently lack effective cures. The transition of Enterococcus gallinarum from a neglected gut resident to a major player in autoimmune and oncology research represents the new frontier of precision medicine. By understanding the "where" and "when" of this bacterium's activity, we can unlock new methods to treat some of the most challenging chronic diseases of our time.
Partner with us today to illuminate the dark corners of the microbiome. Whether you are seeking to inhibit this pathobiont or harness its immunostimulatory power, our CRO services provide the technical excellence and scientific insight to move your project from the bench to the clinic.
Would you like me to prepare a detailed proposal or a specific study design for your E. gallinarum project?
Frequently Asked Questions (FAQs)
Is E. gallinarum considered a pathogen?
It is a "pathobiont." In healthy individuals, it is a harmless commensal. However, in certain genetic backgrounds or under stress, it can translocate and trigger autoimmune responses.
How do you track the translocation of the strain in animal models?
We use bioluminescent or fluorescent tagging (e.g., GFP-labeled strains) combined with ex vivo plating of liver and spleen tissue to quantify the bacterial load in extra-intestinal organs.
Can you help with the development of a vaccine against E. gallinarum?
Yes. We offer preclinical testing for both heat-killed bacterial vaccines and subunit vaccines, measuring antibody titers and the subsequent reduction in systemic inflammation.
How do you handle the vancomycin resistance inherent in this strain?
We perform rigorous AST and genomic profiling to distinguish between intrinsic vanC resistance and acquired resistance, ensuring safety in therapeutic development.
